Due to the pre-clinical and clinical data supporting multi-hit PIK3CA as an actionable target and the high prevalence of PIK3CA mutations in CRC, we aim to identify the prevalence of the mutation, co-occurring mutations, and patient characteristics of multi-hit PIK3CA in CRC. The gene discussed is PIK3CA; the disease is colorectal carcinoma.